IQWiG finds major benefits of Xtandi for Prostate Cancer - Astellas
According to the German Institute for Quality and Efficiency in Health Care (IQWiG), Xtandi (enzalutamide), from Astellas, shows an indication and hint of major added benefit for patients with metastatic Prostate Cancer. In November 2013, the IQWiG determined an added benefit of this drug over the appropriate comparator therapy. But based on data subsequently provided by the manufacturer in the commenting procedure, the Institute has come to a different conclusion in an addendum: there is an indication of a major added benefit in the patient group without visceral metastases.
In patients with visceral metastases, there is a hint of a major added benefit. Strong painkillers, which are often associated with severe side effects, had to be used less frequently than under BSC alone, for example.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)